Ultra-small implanted neurostimulation device for the treatment of Obstructive Sleep Apnea

Información del proyecto

Nyxoah

Identificador del acuerdo de subvención: 729044

DOI

10.3030/729044

Proyecto cerrado

Fecha de la firma de la CE 21 Mayo 2016

Fecha de inicio 1 Junio 2016

Fecha de finalización 30 Septiembre 2016

Financiado con arreglo a

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coste total

€ 71 429,00

Aportación de la UE

€ 50 000,00

Coordinado por

NYXOAH SA
Belgium

Periodic Reporting for period 1 - Nyxoah (Ultra-small implanted neurostimulation device for the treatment of Obstructive Sleep Apnea)

Período documentado: 2016-06-01 hasta 2016-09-30

Resumen del contexto y de los objetivos generales del proyecto

Nyxoah project aims to introduce to the market a tiny HypoGlossal Nerve Stimulation (HGNS) system for the treatment of moderate to severe OSA patients who are not compliant with CPAP therapy. The key objectives of the project are to gather sufficient clinical evidence to commercialise the system as a CE certified medical device in Europe.

Trabajo realizado desde el comienzo del proyecto hasta el final del período abarcado por el informe y los principales resultados hasta la fecha

During the Phase 1 Feasibility Assessment, Nyxoah accomplished a full analysis of the business potential of the Nyxoah’s GenioTM. Throughout the duration of the project, Nyxoah increased its knowledge of the medical device market, including regulations, medical device reimbursement standards, market size and competitors.
In the feasibility study, Nyxoah estimated that there are around 4.6 million OSA sufferers in Europe who need an alternative solution to treat this sleep disorder breathing. Nyxoah decided to primarily target already diagnosed patients who are non-compliant with CPAP (700K) or refuse CPAP (100K), sizing the potential market at 800K patients.

Avances que van más allá del estado de la técnica e impacto potencial esperado (incluida la repercusión socioeconómica y las implicaciones sociales más amplias del proyecto hasta la fecha)

Nyxoah’s disruptive technology will promote health and wellbeing, and improve patient quality of life. Nyxoah proposes an innovative OSA treatment for patients and sleep specialists. Nyxoah’s GenioTM will offer a minimally invasive, effective and easy-to-use OSA alternative therapy to millions of OSA sufferers and thousands of sleep specialists.

Nyxoah’s GenioTM implant

Nyxoah’s GenioTM patch

Nyxoah’s GenioTM